Atovaquone
- Generic Name
- Atovaquone
- Brand Names
- Malarone, Mepron
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19ClO3
- CAS Number
- 95233-18-4
- Unique Ingredient Identifier
- Y883P1Z2LT
- Background
Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
- Indication
主要用于治疗恶性疟原虫感染（对氯喹敏感或耐药者）；还可用于艾滋病患者合并卡氏肺囊虫病或弓形原虫性脑炎等治疗以及轻中度不能耐受复方磺胺药的肺孢子菌肺炎（PCP肺炎）。
- Associated Conditions
- Malaria caused by Plasmodium falciparum, Pneumocystis Jirovecii Pneumonia, Toxoplasma gondii encephalitis, Acute, uncomplicated Malaria caused by plasmodium falciparum, Mild Babesiosis, Mild Pneumocystis jiroveci pneumonia, Moderate Babesiosis, Moderate Pneumocystis jiroveci pneumonia
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT01858831
- Locations
- 🇯🇵
GSK Investigational Site, Kagoshima, Japan
Antiretroviral Drug Interaction Study in Volunteers With HIV
- Conditions
- HIVToxoplasmosisPCP
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2018-07-05
- Target Recruit Count
- 36
- Registration Number
- NCT01479361
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Weekly Dosing of Malarone ® for Prevention of Malaria
- Conditions
- Malaria
- Interventions
- Other: Procedure - malaria challenge
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Target Recruit Count
- 35
- Registration Number
- NCT00984256
- Locations
- 🇺🇸
Walter Reed Army Institute of Research, Silver Spring, Maryland, United States
Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
- Conditions
- HIV InfectionsMalaria
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 79
- Registration Number
- NCT00421473
- Locations
- 🇳🇱
Alysis Zorggroep loc. Rijnstate, Arnhem, Gelderland, Netherlands
🇳🇱Elisabeth hospital, Tilburg, Brabant, Netherlands
🇳🇱Erasmus MC, Rotterdam, Zuid Holland, Netherlands
A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX
- Conditions
- Pneumonia, Pneumocystis CariniiHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 615
- Registration Number
- NCT00002340
- Locations
- 🇺🇸
Holmes Hosp, Cincinnati, Ohio, United States
🇺🇸Hampton Roads Med Specialists, Hampton, Virginia, United States
🇺🇸Bay Area AIDS Consortium, Tampa, Florida, United States
Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children
- Conditions
- Pneumonia, Pneumocystis CariniiHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 24
- Registration Number
- NCT00000773
- Locations
- 🇺🇸
Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
🇺🇸St. Jude/UTHSC CRS, Memphis, Tennessee, United States
🇺🇸Chicago Children's CRS, Chicago, Illinois, United States
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
- Conditions
- Bacterial InfectionsPneumonia, Pneumocystis CariniiHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 690
- Registration Number
- NCT00000811
- Locations
- 🇺🇸
Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States
🇵🇷San Juan City Hosp, San Juan, Puerto Rico
🇺🇸Texas Children's Hosp / Baylor Univ, Houston, Texas, United States
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis
- Conditions
- HIV InfectionsToxoplasmosis, Cerebral
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 100
- Registration Number
- NCT00000794
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
- Conditions
- Toxoplasmosis, CerebralHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00001994
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Gathe, Joseph, M.D., Houston, Texas, United States
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
- Conditions
- Pneumonia, Pneumocystis CariniiHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00001996
- Locations
- 🇺🇸
UCI Med Ctr, Orange, California, United States
🇺🇸Cedars Sinai Med Ctr, Los Angeles, California, United States
🇺🇸AIDS Community Research Consortium, Redwood City, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.